

AUTHOR INDEX

- Abdul-Karim, F.W., 96
 Abi-Rached, B., 42
 Allegra, C.J., 418
 Anasetti, C., 405
 Appelbaum, F.R., 405

Belldegrun, A., 1, 74
 Berkowitz, R.S., 157, 166
 Biggs, D., 230
 Bilgrami, S., 307
 Brand, R., 448
 Buckner, C.D., 405
 Busch, E., 494
 Butturini, A., 374

Chapman, A.E., 17
 Clift, R., 405
 Cohen, S.C., 218
 Coia, L.R., 611
 Cormis, R.L., 571
 Creaven, P.J., 509
 Crilley, P., 238

DeBaz, B.P., 130
 Debruyne, F.M.J., 34
 Dewald, G.W., 341
 Dickstein, J.I., 355
 Doll, D.C., 305

Feldman, S., 166
 Fenton, R.G., 9
 Figlin, R.A., 1, 74
 Freedman, G.M., 611
 Friedland, D.M., 571
 Fuchs, C.S., 472

Gabrail, N.Y., 305
 Gale, R.P., 374
 Gewirtz, A.M., 210
 Ghosh, P., 9
 Giralt, S., 396
 Gnarra, J.R., 3
 Goldfarb, J.M., 193
 Goldstein, D.P., 157, 166
 Goldstein, L.J., 17, 238
 Greenberg, B.R., 307
 Greenfield, A.W., 142

Gregorio, T.A., 9
 Grossman, S.A., 530

Haller, D.G., 415
 Harris, D.T., 529, 553
 Herrington, S., 185
 Hoagland, H.C., 334
 Holderman, K., 448

Jacobs, C., 540
 Jaffee, E.M., 81
 Johnston, P.G., 418

Kantarjian, H., 396
 Kantoff, P.W., 625
 Kelsen, D.P., 582
 Kemeny, M.M., 494
 Kennedy, A.W., 161
 Klumpp, T.R., 263
 Komschlies, K.L., 9
 Kotz, K.W., 250
 Krigel, R.L., 218

Lage, J.M., 113
 Lerman, M.I., 3
 Lewis, T.L., 130
 Linehan, M., 3
 List, A.F., 305
 Longo, D.L., 9
 Loret de Mola, J.R., 193

Macfee, M.S., 95, 109
 Mangan, K.F., 202
 Mastrangelo, M.J., 647
 Matamoros, A., 448
 Mayer, R.J., 472
 Meropol, N.J., 509
 Moolten, D.N., 271
 Motzer, R.J., 641
 Murphy, W.J., 9

Nathan, F.E., 647
 Nelson, R.L., 488
 Noel, P., 327
 Norris, L.K., 530
 Novick, A.C., 29

Oosterwijk, E., 34
 Pardoll, D.M., 81
 Parkinson, D.R., 61
 Peirce, W.C., 74
 Petrelli, N.J., 509
 Petrylak, D., 42
 Pinto, H., 540

Radich, J., 405
 Rahgavan, D., 633
 Ratajczak, M.Z., 210
 Redline, R.W., 96
 Rose, P.G., 149

Schalken, J.A., 34
 Schilder, R.J., 250
 Schilsky, R.L., 600
 Semer, D.A., 109
 Shulman, K., 600
 Silverstein, M.N., 327, 334
 Smith, M.R., 625
 Soper, J.T., 172
 Spiers, A.S.D., 380
 Stadler, W.M., 67
 Strom, B.L., 433
 Sznoł, M., 61

Talpaz, M., 396
 Temporo, M., 448
 Terrieri, A., 327, 334
 Topolsky, D., 230
 Tyrey, L., 121

Vardiman, J.W., 355
 Vaughn, D.J., 415
 Vogelzang, N.J., 67

Weinberg, D.S., 433
 Weiner, L.M., 201
 Wiltrout, R.H., 9
 Wolf, N.G., 113
 Wright, P., 341

Yagoda, A., 42

Zbar, B., 3

SUBJECT INDEX

- Ab2 vaccine, in renal cell cancer, 37-40
Ab3 sera, 39
ABL, in chronic granulocytic leukemia, 344
Abortion, spontaneous, in polycythemia rubra vera, 312
Acivicin, in renal cell cancer, 44
Aclarubicin, in renal cell cancer, 44
Actinomycin
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147

Adenosine deaminase deficiency, 281
Adherent lymphokine activated killer cell, 375
Adjuvant chemotherapy
 of brain tumor, 530-539
 in breast cancer, 553-570
 with cisplatin, vinblastine, bleomycin regimen, for testis cancer, 642-643
 in CNS lymphoma, 536
 of colon cancer, 600-610

AUTHOR INDEX

- Abdul-Karim, F.W., 96
 Abi-Rached, B., 42
 Allegra, C.J., 418
 Anasetti, C., 405
 Appelbaum, F.R., 405

Belldegrun, A., 1, 74
 Berkowitz, R.S., 157, 166
 Biggs, D., 230
 Bilgrami, S., 307
 Brand, R., 448
 Buckner, C.D., 405
 Busch, E., 494
 Butturini, A., 374

Chapman, A.E., 17
 Clift, R., 405
 Cohen, S.C., 218
 Coia, L.R., 611
 Cormis, R.L., 571
 Creaven, P.J., 509
 Crilley, P., 238

DeBaz, B.P., 130
 Debruyne, F.M.J., 34
 Dewald, G.W., 341
 Dickstein, J.I., 355
 Doll, D.C., 305

Feldman, S., 166
 Fenton, R.G., 9
 Figlin, R.A., 1, 74
 Freedman, G.M., 611
 Friedland, D.M., 571
 Fuchs, C.S., 472

Gabrail, N.Y., 305
 Gale, R.P., 374
 Gewirtz, A.M., 210
 Ghosh, P., 9
 Giralt, S., 396
 Gnarra, J.R., 3
 Goldfarb, J.M., 193
 Goldstein, D.P., 157, 166
 Goldstein, L.J., 17, 238
 Greenberg, B.R., 307
 Greenfield, A.W., 142

Gregorio, T.A., 9
 Grossman, S.A., 530

Haller, D.G., 415
 Harris, D.T., 529, 553
 Herrington, S., 185
 Hoagland, H.C., 334
 Holderman, K., 448

Jacobs, C., 540
 Jaffee, E.M., 81
 Johnston, P.G., 418

Kantarjian, H., 396
 Kantoff, P.W., 625
 Kelsen, D.P., 582
 Kemeny, M.M., 494
 Kennedy, A.W., 161
 Klumpp, T.R., 263
 Komschlies, K.L., 9
 Kotz, K.W., 250
 Krigel, R.L., 218

Lage, J.M., 113
 Lerman, M.I., 3
 Lewis, T.L., 130
 Linehan, M., 3
 List, A.F., 305
 Longo, D.L., 9
 Loret de Mola, J.R., 193

Macfee, M.S., 95, 109
 Mangan, K.F., 202
 Mastrangelo, M.J., 647
 Matamoros, A., 448
 Mayer, R.J., 472
 Meropol, N.J., 509
 Moolten, D.N., 271
 Motzer, R.J., 641
 Murphy, W.J., 9

Nathan, F.E., 647
 Nelson, R.L., 488
 Noel, P., 327
 Norris, L.K., 530
 Novick, A.C., 29

Oosterwijk, E., 34
 Pardoll, D.M., 81
 Parkinson, D.R., 61
 Peirce, W.C., 74
 Petrelli, N.J., 509
 Petrylak, D., 42
 Pinto, H., 540

Radich, J., 405
 Rahgavan, D., 633
 Ratajczak, M.Z., 210
 Redline, R.W., 96
 Rose, P.G., 149

Schalken, J.A., 34
 Schilder, R.J., 250
 Schilsky, R.L., 600
 Semer, D.A., 109
 Shulman, K., 600
 Silverstein, M.N., 327, 334
 Smith, M.R., 625
 Soper, J.T., 172
 Spiers, A.S.D., 380
 Stadler, W.M., 67
 Strom, B.L., 433
 Sznoł, M., 61

Talpaz, M., 396
 Temporo, M., 448
 Terrieri, A., 327, 334
 Topolsky, D., 230
 Tyrey, L., 121

Vardiman, J.W., 355
 Vaughn, D.J., 415
 Vogelzang, N.J., 67

Weinberg, D.S., 433
 Weiner, L.M., 201
 Wiltrout, R.H., 9
 Wolf, N.G., 113
 Wright, P., 341

Yagoda, A., 42

Zbar, B., 3

SUBJECT INDEX

- Ab2 vaccine, in renal cell cancer, 37-40
Ab3 sera, 39
ABL, in chronic granulocytic leukemia, 344
Abortion, spontaneous, in polycythemia rubra vera, 312
Aciclovic, in renal cell cancer, 44
Aclarubicin, in renal cell cancer, 44
Actinomycin
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147

Adenosine deaminase deficiency, 281
Adherent lymphokine activated killer cell, 375
Adjuvant chemotherapy
 of brain tumor, 530-539
 in breast cancer, 553-570
 with cisplatin, vinblastine, bleomycin regimen, for testis cancer, 642-643
 in CNS lymphoma, 536
 of colon cancer, 600-610

- Adjuvant chemotherapy (*Continued*)
in colorectal cancer, 472-487
definition of, 472, 532
in ependymoma, 536
of gastric cancer, 590-592
goal of, 532
in head and neck cancer, 540-552
in high-grade astrocytoma, 533-534
for invasive bladder cancer, 625-632
in medulloblastoma, 536
for melanoma, 647-661
multi-institutional trials of, in colon cancer, 604
need for, in rectal cancer, 611
neoadjuvant *v.* for invasive bladder cancer, 629-630
in node-negative patients, 554-555, 564-566
in node-positive patients, 553-554, 564
nonsystemic, for melanoma, 656-657
in NSCLC, 571-581
overview of, 529
of pancreatic cancer, 595-596
patient selection for, 585-586
portal vein, 476-477, 604-605
postoperative, timing of, in esophageal cancer, 587
practical considerations in, 564-566
preoperative, in rectal cancer, 611-612
preoperative *v.* postoperative, in rectal cancer, 616-617
in prostate cancer, 633-640
randomized trials of, in NSCLC, 573
rationale for, 474
single agent, in colorectal cancer, 474-475
in stage II nonseminomatous testis cancer, 641-646
surveillance *v.* in testis cancer, 643
trials of, in rectal cancer, 481-482
in upper gastrointestinal tract cancers, 582-599
with folinic acid plus 5-FU, trials of, 602-604
AG337, 515
Age
in choriocarcinoma, 111
in colon cancer, 440
in gestational trophoblastic disease, 110
in matched sibling transplantation, for chronic myelogenous leukemia, 406
polycythemia rubra vera treatment by, 319
Agnogenic myeloid metaplasia
bone marrow fibrosis in, 327-328
clinical features of, 329
cytogenetics of, 348-349
diagnosis of, 328-329
experimental therapy in, 331
medical management of, 330
prognosis in, 329-330
radiation treatment in, 331
splenectomy in, 330-331
Alanosine, in renal cell cancer, 44
Alkylating agents, in renal cell cancer, 52
Allele, chromosome
clinical significance of, 421-422
in colorectal cancer, 419, 421
Amarantrone, in renal cell cancer, 44
Aminothiadazole, in renal cell cancer, 44
Amiodarone, as chemosensitizing agent, 23
Amonafide, in renal cell cancer, 44
Amphotericin B
as chemosensitizing agent, 23
lomustine plus, in renal cell cancer, 48
Ampligen, in renal cell cancer, 44
Amsacrine, in renal cell cancer, 44
A-myb protein, 215
Anagrelide, 319
in agnogenic myeloid metaplasia, 331
in essential thrombocythemia, 337
Anemia
in agnogenic myeloid metaplasia, 329
autoimmune hemolytic, in chronic granulocytic leukemia, 393
in chronic granulocytic leukemia metamorphosis, 392
due to stem cell harvesting, 264
hypoproliferative, 267
Anoikis, 213
Anthracyclines
in adjuvant chemotherapy, for breast cancer, 554
in renal cell cancer, 53
Anti-antibodies, 37-38
Anti-idiotypic antibody, monoclonal antibody G250-related, 37-40
Antibody 3H1, in colorectal cancer, 425-426
Antibody purging, in stem cell collections, 274-275
Antibody therapy, in colorectal cancer, 425
Antifols, in renal cell cancer, 52
Antigen preserving cell, professional, 13
Antigen-supplemented whole tumor cells, for melanoma, 655
Antimitotics, in renal cell cancer, 51-52
Antisense oligonucleotide, 275
apc gene, 419
and *c-myc* activity, 424
Aspirin, in polycythemia rubra vera, 316
Astrocytoma, high-grade
adjuvant chemotherapy of, 533
adjuvant chemotherapy results in, 533-534
carmustine adjuvant therapy in, 533-534
carmustine neoadjuvant therapy in, 535-536
cisplatin neoadjuvant therapy in, 535-536
dissemination of, 531-532
intra-arterial chemotherapy in, 534
neoadjuvant therapy of, 535
neoadjuvant therapy results in, 535-536
procarbazine, lomustine, vincristine regimen in, 533
survival in, 533
ATP binding cassette, 17
Atypical myeloproliferative syndrome, cardinal features of, 381
Autolymphocyte cellular therapy, in renal cell cancer, 74-75
5-Aza-2'-Deoxycytidine, in renal cell cancer, 44
Bacille Calmette-Guerin
in adjuvant therapy, 647-649
in colon cancer, 605-606
for melanoma, 650-652
trials of, in NSCLC, 573-576
Bacteremia, due to stem cell harvesting, 264
Barium enema, in colon cancer screening, 439

- Basic fibroblast growth factor, 214
 Bcl-2 gene, 275
 BCNU, see Carmustine
 BCR, in chronic granulocytic leukemia, 344
 BCR-ABL fusion
 in chronic granulocytic leukemia, 344-345
 in chronic myelogenous leukemia, 374-375
 Bepridil, as chemosensitizing agent, 23
 Biochemical modulation, of 5-FU, in metastatic colorectal cancer, 509-524
 Biologic response modifier, in colon cancer, 606
 Biomarker(s)
 candidate, in colon cancer, 443
 in colon cancer screening, 442
 Bisantrene, in renal cell cancer, 44
 Bladder cancer, invasive
 adjuvant therapy for, 625-632
 neoadjuvant therapy for, 625-632
 treatment recommendations for, 630-631
 Blastic crisis, in chronic granulocytic leukemia metamorphosis, 391
 Bleeding, in polycythemia rubra vera, 311
 Bleomycin
 in neoadjuvant therapy, for head and neck cancer, 541
 in neoadjuvant trials, for head and neck cancer, 542-543
 Bleomycin, cisplatin, vinblastine regimen, as adjuvant therapy, 642-643
 Blighted ovum, 98
 Blindness, monocular, in polycythemia rubra vera, 312
 Blood center, in PBSC transplantation, 283-284
 Blood transfusion, in hepatic resection, 496
 BMT, see Bone marrow transplantation
 B-myb protein, 215
 Bone marrow, in polycythemia rubra vera, 313
 Bone marrow fibrosis
 causes of, 328
 diagnosis of, 328-329
 pathogenesis of, 327-328
 Bone marrow transplantation
 allogeneic
 in chronic myelogenous leukemia, 397-398
 in multiple myeloma, 231-232
 autologous
 in chronic myelogenous leukemia, 408
 in high-dose chemotherapy trials, 563
 in metastatic breast cancer, 240-242
 in multiple myeloma, 232
 v peripheral progenitor cell transplant, 242-243
 CA-125 in, 258-259
 cures due to, in chronic myelogenous leukemia, 409-410
 HLA-identical sibling, in chronic myelogenous leukemia, 405-407
 matched sibling, in advanced chronic myelogenous leukemia, 407
 mismatched family member, in chronic myelogenous leukemia, 407
 unrelated donor, in chronic myelogenous leukemia, 407-408
 Brain tumor, primary
 adjuvant chemotherapy of, 530-539
 common intracranial, 531
 incidence of, 530
 Brain tumor, primary (*Continued*)
 neoadjuvant chemotherapy of, 530-539
 radiotherapy of, 185-188, 530
 Breast cancer
 adjuvant chemohormonal therapy in, 556-558
 adjuvant hormonal therapy in, 555-556
 adjuvant systemic therapy in, 553-570
 autologous BMT v, peripheral progenitor cell transplant in, 242-243
 bone marrow support in, 240-242
 chemotherapy dose intensity in, 238-240, 561-563
 chemotherapy dose intensity trials in, 559
 chemotherapy dose sequencing in, 563-564
 cyclophosphamide, methotrexate, 5-FU regimen in, 553
 high-dose chemotherapy trials in, 563
 high-dose therapy in, 240-242
 metastatic, 240-242
 national randomized trials in, of high-dose therapy, 242
 node-negative, adjuvant chemotherapy in, 554-555, 564-566
 node-positive, adjuvant chemotherapy in, 553-554, 564
 ovarian ablation in, 558-559
 overview analysis in, 560-561
 peripheral blood stem cell transplantation in, 238-249
 stage II, 242
 stage III, 242
 Budd-Chiari syndrome, in polycythemia rubra vera, 312
 Burst-forming units-erythroid, 308
 Busulfan
 in chronic granulocytic leukemia, 387-388
 in chronic myelogenous leukemia, 396-397
 in matched sibling BMT, 406
 in peripheral blood progenitor cell transplantation, 233
 in polycythemia rubra vera, 317
 Busulfan lung, 387
 Bystander effect, 282-283
 CA 19-9 antigen, radioimmunodetection of, 448
 CA-125, in BMT, 258-259
 Camptothecin, 515-516
 Carbohydrates, in human chorionic gonadotropin, 123
 Carboplatin
 cisplatin v, in ovarian cancer, 251
 high-dose, 251
 in high-dose combination regimen, for ovarian cancer, 256-257
 in neoadjuvant therapy, for head and neck cancer, 541
 in renal cell cancer, 44
 Carcinoembryonic antigen
 in colorectal cancer, 425-426
 in liver metastasis detection, 495
 radioimmunodetection of, 448
 Cardiac valve, abnormalities of, in polycythemia rubra vera, 312
 Carmustine
 as adjuvant therapy, in high-grade astrocytoma, 533-534
 etoposide, cytarabine, cyclophosphamide regimen, high-dose, 220
 etoposide, cytarabine, melphalan regimen, high-dose, 220
 in neoadjuvant therapy, for high-grade astrocytomas, 535-536
 in peripheral blood progenitor cell transplantation, 233
 Catheter, central venous, occlusion of, 263-264
 CB3717, 515

- CCNU, see Lomustine
CD34 antigen
 direct positive selection of, 204-205
 identification of, 203
CEA, see Carcinoembryonic antigen
Cell proliferation, detection of, in colon cancer, 442
Cell staining, in stem cell tumor detection, 273
Cellular therapy
 autolymphocytes for, 74-75
 in renal cell cancer, 74-80
 LAK cells for, 75-76
 tumor-infiltrating lymphocytes for, 76-78
Central nervous system
 gestational trophoblastic disease metastatic to, 137-139
 high-risk gestational trophoblastic disease metastatic to, 179
Central venous cathether, occlusion of, 263-264
Centrifugation, for stem cell isolation, 212
Chemoembolization, for hepatic metastases, 503
Chemohormonal therapy, adjuvant, in breast cancer, 556-558
Chemoimmunotherapy, in colon cancer, 606
Chemokines, transfectants for, 13-14
Chemoprophylaxis
 data supporting, 157-158
 of hydatidiform mole, 157-160
 opposition to, 158
Chemoradiotherapy
 concurrent, 545-547
 in esophageal cancer, 589-590
 in gastric cancer, 593
 in head and neck cancer, 545-548
 in NSCLC, 578-579
 postoperative, in rectal cancer, 613-616
 preoperative, trials of, 613
 without surgery, in esophageal cancer, 589
 in upper gastrointestinal tract cancers, 584-585
Chemosensitizing agents, 23
Chemotherapy
 adjuvant, see Adjuvant chemotherapy
 in breast cancer, 238-240
 combination, see Combination chemotherapy
 dose intensity of, in breast cancer, 561-563
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 hepatic arterial, in colorectal cancer, 501-503
 high-dose, see High-dose chemotherapy
 in high-grade astrocytoma, 533
 in high-risk gestational trophoblastic disease, 177-179
 hormonal therapy plus, see Chemohormonal therapy
 by intrahepatic pump, 502-503
 infertility following, 196
 interstitial, in high-grade astrocytoma, 534
 intra-arterial, in high-grade astrocytoma, 534
 intraperitoneal, in gastric cancer, 594-595
 in ovarian cancer, 250-251
 in PBSC mobilization, 204-205
 perioperative, definition of, 571
 in persistent gestational trophoblastic disease, 162-163
 pregnancy outcome following, 196
 in primary brain tumor, 530-531
 radiotherapy alternating with, in head and neck cancer, 547
 radiotherapy following
- Chemotherapy (Continued)
 in esophageal cancer, 590
 in head and neck cancer, 547
 radiotherapy plus, see Chemoradiotherapy
 regional, in colorectal cancer, 501-503
 toxicities associated with, rescue from, 517-519
 see also Combined modality therapy
Chlorambucil
 acute leukemia following, 314
 in gestational trophoblastic disease, 177
 in polycythemia rubra vera, 315
CHOP regimen, see Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
Chorioadenoma destruens, sonography in, 131
Choriocarcinoma, 101, 116-117
 atypical, 102
 epidemiology of, 110-111
 incidence of, 111
 metastatic, 138
 MRI of, 136
 pathology of, 103-104
 prognostic factors in, 104
 risk factors for, 111
 sonography of, 131-132
Chromosome 17p, in colorectal cancer, 420-421
Chromosome 18q, in colorectal cancer, 420-421
Chromosome abnormality(ies)
 clonality of, 343
 in myeloproliferative disorders, 341-354
 secondary, 343
Chromosome allele
 clinical significance of, 421-422
 in colorectal cancer, 419, 421
Chromosome evolution, 343
Chronic granulocytic leukemia
 accelerated phase in, 359
 atypical presentation of, 385-387
 blast phase in, 358
 busulfan in, 387-388
 cardinal features of, 381
 chronic phase in, 355
 clinical features of, in metamorphosis, 388-392
 clinical manifestations of, 380-395
 clinical picture of, following initial therapy, 387-388
 clinical presentations of, 381-385
 cytogenetics of, 344-346
 definition of, 380
 diagnosis of, 360, 381, 384, 387
 differential diagnosis of, 358-362
 early, 381-382
 epidemiology of, 380-381
 hematopathologic findings in, 355
 history in, 381, 382, 385

- Chronic granulocytic leukemia (*Continued*)
 hydroxyurea in, 387-388
 interferon alpha in, 387-388
 laboratory features in, 393-394
 major features of, 368
 management of, 382, 384-385, 387
 in metamorphosis, hematological changes during, 391
 metamorphosis progression in, 392-393
 peripheral blood findings in, 381, 383-384, 386-387
 Ph-negative, 346
 physical examination in, 381, 382-383, 385-386
 radiologic findings in, 381, 383, 386
 typical presentation of, 382-385
- Chronic idiopathic myelofibrosis
 characteristics of, 367-368
 evolution of, 368
 major features of, 368
 marrow fibrosis diagnosis and, 368-369
- Chronic myelogenous leukemia
 accelerated-phase, therapy in, 400
 advanced-phase, matched sibling transplantation in, 407
 as cancer development model, 374-379
 atypical, 360-362
 autologous BMT in, 408
 blastic-phase of, therapy in, 400-401
 BMT cures in, 409-410
 BMT for, 405-411
 chronic-phase, matched sibling transplantation in, 405-407
 diagnosis of, 360
 early chronic phase of, therapy for, 397-398
 hematopoiesis, in chronic phase, 375
 HHT in, 401
 HLA-identical sibling transplantation in, 405
 investigational therapies for, 401
 minimal residual disease in, following BMT, 408-409
 mismatched family member BMT in, 407
 peripheral blood stem cell transplantation in, 401
 post-transplant relapse in, 409
 syngeneic transplantation in, 405
 therapeutic goals in, 396-397
 transformation in, 374-375
 treatment of, 396-404
 unrelated donor BMT in, 407-408
- Chronic myelomonocytic leukemia, 360-362
 cardinal features of, 381
 diagnosis of, 360
- Chronic neutrophilic leukemia, 360
 cardinal features of, 381
 characteristics of, 361
- Cimetidine
 coumarin plus, 44
 interferon plus, 44
- Ciprofloxacin, 562
- Cisplatin
 carboplatin *v.* in ovarian cancer, 251
 in chemoradiotherapy
 for head and neck cancer, 546-547
 for NSCLC, 578
 high-dose, 251
 in high-dose combination regimen, for ovarian cancer, 256-257
- Cisplatin (*Continued*)
 high-dose trials of, in breast cancer, 563
 for invasive bladder cancer, 625, 627
 in neoadjuvant therapy
 for head and neck cancer, 541
 for high-grade astrocytomas, 535-536
 in neoadjuvant trials, for head and neck cancer, 542-543
 randomized trials of, in NSCLC, 577
 in refractory ovarian cancer, 251-252
 trials of, in NSCLC, 573-576
- Cisplatin, doxorubicin, cyclophosphamide regimen, for invasive bladder cancer, 625, 627
- Cisplatin, etoposide regimen, as adjuvant therapy
 results of, 644
 in testis cancer, 644
- Cisplatin, 5-FU regimen, in head and neck cancer, 540
- Cisplatin, 5-FU, etoposide regimen, in gastric cancer, 592-593
- Cisplatin, 5-FU, radiotherapy regimen, in head and neck cancer, 547-548
- Cisplatin, methotrexate, vinblastine regimen, for invasive bladder cancer, 625, 627
- Cisplatin, vinblastine, bleomycin regimen, as adjuvant therapy, 642-643
- Classification
 CPV, of choriocarcinoma, 104
 Elston, 104
 FIGO, of gestational trophoblastic disease, 145, 174
 Hertig system of, 101
 NIH, of gestational trophoblastic disease, 146
- Clomipramine, as chemosensitizing agent, 23
- Clone(s)
 chromosomally abnormal, origin of, 343
 multiple, 343-344
 sub-, 343
- C-myc protein, functional map of, 215
- c-myc oncogene, in colorectal cancer, 423-424
- Colectomy, prophylactic, 418
- Colon cancer
 adjuvant immunotherapy in, 605-606
 adjuvant portal vein chemotherapy in, 604-605
 adjuvant therapy of, 600-610
 age in, 440
 barium enema evaluation in, 439
 cell proliferation detection in, 442
 chemoimmunotherapy in, 606
 colonoscopy screening in, 439
 fecal occult blood test screening in, 434-435
 fecal occult blood test trials in, 436-437
 future screening strategies for, 441-443
 historic trials in, 601
 incidence of, 489
 levamisole plus 5-FU in, 601-602
 markers for, 442
 mortality due to, 489
 multi-institutional adjuvant trials in, 604
 national screening cost for, 441
 ornithine decarboxylase detection in, 442-443
 positive family history in, screening and, 440-441
 postoperative irradiation therapy in, 606-607
 potential prognostic indicators in, 601
 prognostic factors in, 600

- Colon cancer (*Continued*)
protein kinase-C detection in, 442-443
screening for, 433-447
screening intervals in, 440
screening personnel for, 441
screening recommendations in, 435
screening strategies in, 439-441
sigmoidoscopy screening in, 437-439
sporadic, incidence of, 440-441
- Colonoscopy, in colon cancer screening, 439
- Colony stimulating factor, granulocyte, *see* Granulocyte-colony stimulating factor
- Colony-forming units-erythroid, 308
- Colony-forming units-granulocyte-erythroid-macrophage-mega-karyocyte, 308
- Colony-forming units-megakaryocyte, 309
- Colony-stimulating factor
for chemotherapy toxicity rescue, 518-519
granulocyte-macrophage, 308
tumor vaccine cells and, 86
- Colorectal cancer
adjuvant chemotherapy in, 472-487
adjuvant immunotherapy in, 481
allelic loss in, 419-422
biology of, clinical implications of, 418-432
CEA monitoring cost in, 491
cellular oncogenes in, 423-424
chemotherapeutic targets in, 426-428
combination chemotherapy in, 475-476
comparative imaging studies in, 464
CT in, 457-461
cytokeratin antigen 17-1A in, 425
DNA ploidy in, 424-425
endoluminal ultrasound in, 452-456
endosonographic staging in, 453-455
failure patterns in, 473-474
follow-up in, cost of, 492
5-FU, levamisole regimen in, 427-428
5-FU biochemical modulation in, 509-524
genetic model for, 419
genomic instability in, 422-423
hepatic-directed therapy in, 494-508
hereditary factors in, 418-419
hereditary nonpolyposis, 418-419
incidence of, 418
intraoperative ultrasound in, 456-457
irinotecan in, 516
leucovorin, 5-FU regimen in, 480-481
levamisole, 5-FU regimen in, 479
levamisole adjuvant therapy in, 477-480
meta-analysis in, 490-492
metastatic disease detection in, 494-495
metastatic survival in, 494
methyl lomustine, 5-FU, vincristine regimen in, 427-428
MRI detection of, 458-459
MRI in, 457-462
MRI staging of, 458-459
mucins in, 426
new imaging techniques in, 448-471
ongoing adjuvant trials in, 482-483
PET in, 462-466
- Colorectal cancer (*Continued*)
portal vein therapy in, 476-477
postoperative evaluation in, 488-493
prognostic factors in, 472-473
radioimmunodetection of, 448-451
radioimmunodetection trials in, 449-451
recent advances in, 415-417
recurrent
curative therapy for, 489-490
endosonographic evaluation of, 455-456
MRI detection of, 459-461
PET imaging in, 464-465
regional chemotherapy in, 501
screening for, 433-447
single agent adjuvant therapy in, 474-475
sporadic nonfamilial, 419-422
staging of, 472-473
systemic chemotherapy in, 500
time trend analysis in, 490
tumor associated antigens in, 425-426
tumor suppressor genes in, 419-422
- Combination chemotherapy
in high-grade astrocytoma, 533
in NSCLC, 579
radiotherapy plus
in head and neck cancer, 545-547
randomized trials of, 546
- Combined modality therapy
adjuvant, in esophageal cancer, 587-590
in head and neck cancer, 548
- Complementary determining regions, 448
- Complete response, definition of, 42
- Computed tomography
in colorectal cancer, 457-461
in gestational trophoblastic disease, 134
portography, for liver metastasis detection, 494
- Conceptus, examination of, methods of, 117-118
- Contig, definition of, 4
- Corynebacterium parvum*, for melanoma, 652-653
- Cost
of CEA monitoring, in colorectal cancer, 491
of colorectal cancer follow-up, 492
of national colon cancer screening, 441
- Cost effectiveness, of high-dose chemotherapy, 244-245
- COU-1, in radioimmunodetection, 451
- Coumarin, cimetidine plus, in renal cell cancer, 44
- Counterflow centrifugal elutriation, 212
- CPT-11, 516
- CPV classification, of choriocarcinoma, 104
- C-reactive protein, plasma levels of, in reactive thrombocytosis, 336
- Cryopreservation, of stem cells, complications of, 264, 268-269
- Cryosurgery, for hepatic metastases, 503-504
- Cryotherapy, in chemotherapy rescue, 519
- CT, *see* Computed tomography
- Cutaneous melanoma, *see* Melanoma, cutaneous
- Cyclophosphamide, 177, 655
in chemoradiotherapy, for NSCLC, 578
- cytarabine plus-, 220
- etoposide plus-, 220
- dose intensity of, in breast cancer, 561-563

- Cyclophosphamide (*Continued*)
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 high-dose, in multiple myeloma, 230
 in high-dose combination regimen, for ovarian cancer, 256-257
 in matched sibling BMT, for chronic myelogenous leukemia, 406
 in mobilization, 258
 misonidazole plus, in renal cell cancer, 44
 in peripheral blood progenitor cell transplantation, for multiple myeloma, 233
 postoperative, in gastric cancer, 590-592
 in prostate cancer, 637
 randomized trials of, in NSCLC, 577
 trials of, in NSCLC, 573-576
- Cyclophosphamide, cisplatin, doxorubicin regimen, for invasive bladder cancer, 625, 627
- Cyclophosphamide, doxorubicin, 5-FU regimen, in breast cancer, 238-240
- Cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen, in CNS lymphomas, 537
- Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, in CNS lymphomas, 537
- Cyclophosphamide, etoposide, cytarabine, regimen, high-dose, 220
- Cyclophosphamide, methotrexate, 5-FU regimen
 in breast cancer, 238-240, 553
 in chemohormonal therapy, for breast cancer, 557
- Cyclophosphamide, methotrexate, procarbazine regimen, intra-arterial, in astrocytoma, 535
- Cyclosporine A
 as chemosensitizing agent, 23
 vinblastine plus, in renal cell cancer, 50
- Cystitis, hemorrhagic, due to stem cell harvesting, 264
- Cytarabine, 594
 in chronic myelogenous leukemia, 398
 in high-dose therapy regimen, 220
 postoperative, in gastric cancer, 590-592
- Cytogenetic abnormalities, in polycythemia rubra vera, 313
- Cytokeratin antigen
 17-1A, 425
 in colorectal cancer, 425-426
- Cytokine(s)
 in chemotherapy toxicity rescue, 519
 delivery of, 14
 genes encoding, in tumor cells, 83-84
- Cytosan, *see Cyclophosphamide*
- Dacarbazine
 for melanoma, 650-652, 654
 in adjuvant therapy, 647-649
- Dactinomycin, 177
 in gestational trophoblastic disease, 147
- 10-Deaza-aminopterin, in renal cell cancer, 45
- del(12)(p12), in myeloproliferative disorders, 341, 342
 del(13)(q12q14), in myeloproliferative disorders, 341, 342, 348-349
 del(20)(q11), 350-351
 in myeloproliferative disorders, 341, 342
 del(5)(q13q33), in myeloproliferative disorders, 341, 342
- Deleted in colon cancer gene, location of, 420-421
- Density gradient centrifugation, 212
- Deoxycoformycin, in renal cell cancer, 45
- Designer drug, for thymidylate synthase inhibition, 515
- Dexamethasone, vincristine, doxorubicin regimen, in chronic myelogenous leukemia, 400-401
- Dexamethasone, cyclophosphamide, doxorubicin, vincristine regimen, in CNS lymphomas, 537
- Diaminocyclohexane platinum complex, 517
- Diaziquone, 533
 in renal cell cancer, 45
- Dideamin-B, in renal cell cancer, 45
- Diltiazem, as chemosensitizing agent, 23
- Dinitrochlorobenzene, pre- and postoperative, for melanoma, 652
- Dinitrophenol, 655
- Dinucleotide repeat, in colorectal cancer, 422
- Diploidy, diandric, 114-115
- Dipyridamole
 in polycythemia rubra vera, 316
 vinblastine plus, 50
- DNA
 methylation of, in colorectal cancer, 421
 tumor, phenotype in, 422-423
- DNA binding domain, 215
- DNA ploidy
 in colorectal cancer, 424-425
 in head and neck cancer, 549
 as prognostic factor, in colorectal cancer, 473
- DNA probe, with fluorescence in situ hybridization, 341
- Doppler ultrasound, in gestational trophoblastic disease, 133-134
- Dose intensity, of chemotherapy, in ovarian cancer, 250-251
- Doxifluridine, 513-514
- Doxorubicin
 in adjuvant therapy, for breast cancer, 553-554
 dose intensity of, in breast cancer, 561-563
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 for invasive bladder cancer, 625, 627
 postoperative, in gastric cancer, 590-592
 trials of, in NSCLC, 573-576
 vinblastine plus, in renal cell cancer, 50
- Doxorubicin, cisplatin, cyclophosphamide regimen, for invasive bladder cancer, 625, 627
- Doxorubicin, cyclophosphamide, 5-FU regimen, in breast cancer, 238-240
- Doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen, in CNS lymphomas, 537
- Doxorubicin, cyclophosphamide, vincristine, prednisone regimen, in CNS lymphomas, 537
- Doxorubicin, methotrexate, 5-FU regimen, in gastric cancer, 593
- Doxorubicin, methotrexate, vinblastine regimen, for invasive bladder cancer, 625, 627
- Doxorubicin, vincristine, dexamethasone regimen, in chronic myelogenous leukemia, 400-401
- DTIC, *see Dacarbazine*
- Duke's stage, of colorectal cancer, DNA ploidy and, 424-425
- Echinomycin, in renal cell cancer, 45
- Elliptinium, in renal cell cancer, 45

- Elston classification, of choriocarcinoma, 104
Endoluminal ultrasound
 in colorectal cancer, 452-456
 future colorectal applications of, 456
 for lymph node assessment, 455
 in sphincter-saving surgery, 455
Endosonography, *see* Endoluminal ultrasound
Enzyme-linked immunosorbent assay, of human chorionic gonadotropin, 125-126
Ependymoma
 adjuvant therapy of, 536-537
 neoadjuvant therapy of, 536-537
Epidermal growth factor receptor, in head and neck cancer, 549
Epirubicin
 dose intensity of, in breast cancer, 562-563
 in neoadjuvant therapy, for head and neck cancer, 541
 in renal cell cancer, 45
Epithelial growth factor, in chemotherapy rescue, 519
Epithelial membrane antigen, radioimmunodetection of, 448
Erythrocytosis
 in polycythemia rubra vera diagnosis, 312
 secondary, erythropoietin levels in, 308
Erythroleukemia, 392
Erythromelalgia, in polycythemia rubra vera, 312
Erythropoietin
 in secondary erythrocytosis, 308
 normal levels of, 308
 secretion of, in polycythemia rubra vera, 307-308
Erythropoietin receptor, in polycythemia rubra vera, 310
Esophageal cancer
 adjuvant combined modality therapy in, 587-590
 adjuvant therapy in, 582-599
 chemoradiotherapy in, 584-585
 failure pattern in, 582-584
 incidence of, 582
 neoadjuvant therapy of, 584
 patient selection in, 585-586
 postoperative chemotherapy in, 586-587
 resection in, survival following, 585
 surgery in, 586-587
Esophagectomy, transhiatal, in esophageal cancer, 586
Esrubicin, in renal cell cancer, 45
Essential thrombocythemia
 cytogenetics of, 349
 definition of, 349
 diagnosis of, 335
 diagnostic criteria for, 335, 364
 differential diagnosis of, 366-367
 evolution of, 366
 major features of, 368
 morphologic findings in, 364-366
 pathogenesis of, 334-335
 pregnancy and, 338-339
 prognosis in, 336-33337
 reactive thrombocytosis v, 335
 treatment of, 337-338
 in young patients, 338
Estramustine phosphate, in prostate cancer, 637
Ethanol, percutaneous injection therapy with, for hepatic metastases, 504
Ethynodiolide, in 5-FU biochemical modulation, 514
Etoposide
 in gestational trophoblastic disease, 147
 in high-dose combination regimen, 220, 256-257
 in matched sibling BMT, for chronic myelogenous leukemia, 406
 in mobilization, 258
 for ovarian cancer, 256-257
 in peripheral blood progenitor cell transplantation, for multiple myeloma, 233
 randomized trials of, in NSCLC, 577
Etoposide, cisplatin regimen, as adjuvant therapy, in testis cancer, 644
Etoposide, cisplatin, 5-FU regimen, in gastric cancer, 592-593
Europium, 126
Familial adenomatous polyposis, hereditary factors in, 418-419
Family history, in colon cancer screening, 440-441
FDG, in PET imaging, 463
Fecal occult blood test
 in average risk persons, 436-437
 in colon cancer, 434-435
 controlled trials of, 436
 false-negative, causes of, 435
 false-positive, causes of, 435
Fetal pole, 98
Fibroblast, for gene therapy, 14
Fibroblast activation protein, radioimmunodetection of, 448
FIGO staging, 174
 of gestational trophoblastic disease, 145
Flavone-8-acetic acid, 10
Flavonoids, definition of, 10
Flow cytometry
 in gestational trophoblastic disease, 106
 in stem cell tumor detection, 273
Flouxuridine
 folinic acid plus, 46
 interferon plus, 46
 postoperative, in gastric cancer, 590-592
 vinblastine plus, 46
Flouxuridine, folinic acid, interferon regimen, in renal cell cancer, 46
Fludarabine, in renal cell cancer, 46-47
Flunarizine, as chemosensitizing agent, 23
Fluorescence in situ hybridization, DNA probe with, 341
Fluorodeoxyglucose, in PET imaging, 463-464
Fluorouracil
 in adjuvant therapy, for breast cancer, 553-554
 biochemical modulation of, in metastatic colorectal cancer, 509-524
 biochemical modulation trials of, 512
 bolus v protracted venous infusion of, in rectal cancer, 615
 in chemoradiotherapy
 for head and neck cancer, 546-547
 for rectal cancer, 614
 in colorectal cancer, 426-428, 474-475, 479
 dose intensity of, in breast cancer, 561-563
 dose sequencing of, in breast cancer, 563-564
 folinic acid plus, 47
 history of, 509
 interferon plus, 47
 for invasive bladder cancer, 625, 627

- Fluorouracil (Continued)**
- interferon-alpha biochemical modulation of, 511-513
 - leucovorin biochemical modulation of, 509-511
 - leucovorin plus, in colorectal cancer, 480-481
 - metabolic pathways of, 510
 - in neoadjuvant therapy, for head and neck cancer, 541
 - in neoadjuvant trials, for head and neck cancer, 542-543
 - PALA biochemical modulation of, 511
 - postoperative, in gastric cancer, 590-592
 - prodrugs of, 513-514
 - in prostate cancer, 638
 - semustine plus, in colorectal cancer, 475
 - uracil plus, 47
 - Fluorouracil, cisplatin regimen, in head and neck cancer, 540
 - Fluorouracil, cisplatin, etoposide regimen, in gastric cancer, 592-593
 - Fluorouracil, cisplatin, radiotherapy regimen, in head and neck cancer, 547-548
 - Fluorouracil, cyclophosphamide, doxorubicin regimen, in breast cancer, 238-240
 - Fluorouracil, cyclophosphamide, methotrexate regimen in breast cancer, 553
 - dose intensity of, 238-240
 - Fluorouracil, folinic acid regimen, adjuvant, trials of, 602-604
 - Fluorouracil, folinic acid, levamisole regimen, adjuvant, trials of, 604
 - Fluorouracil, methotrexate, doxorubicin regimen, in gastric cancer, 593
 - Flutamide, interferon plus, in renal cell cancer, 47
 - Folinic acid
 - in adjuvant chemotherapy, for colorectal cancer, 474-475
 - in chemoradiotherapy, for rectal cancer, 617-618
 - flouxuridine plus, in renal cell cancer, 46
 - ftorafur plus, 513
 - in 5-FU biochemical modulation, 509-511
 - in gestational trophoblastic disease, 147
 - high-dose trials of, in breast cancer, 563
 - mechanism of action of, 427
 - in neoadjuvant therapy
 - for colorectal cancer, 474-475
 - for head and neck cancer, 541 - Folinic acid, flouxuridine, interferon regimen, in renal cell cancer, 46
 - Folinic acid, fluorouracil regimen
 - adjuvant, trials of, 602-604
 - in colorectal cancer, 480-481
 - in renal cell cancer, 47 - Folinic acid, fluorouracil, levamisole regimen, adjuvant, trials of, 604
 - Fosquidone, in renal cell cancer, 47
 - Fotemustine, in renal cell cancer, 47
 - Ftorafur
 - development of, 513
 - postoperative, in gastric cancer, 590-592 - 5-FU, see Fluorouracil
 - G-protein, 419-420
 - Gallium nitrate
 - for invasive bladder cancer, 625
 - in renal cell cancer, 47 - GAP, 214
 - Gardener's syndrome, hereditary factors in, 418-419
 - Gastric cancer
 - adjuvant therapy in, 582-599
 - chemoradiotherapy in, 584-585, 593
 - failure pattern in, 582-584
 - immunochemotherapy in, 593-594
 - incidence of, 582
 - intraperitoneal chemotherapy in, 594-595
 - neoadjuvant therapy in, 584, 592-593
 - patient selection in, 585-586
 - postoperative chemotherapy in, 586-587, 590-592
 - resection in, survival following, 585
 - surgery in, 586-587 - GATA-1, 215
 - Gemcitabine, in renal cell cancer, 47
 - Gene(s)
 - for drug sensitivity, 282
 - mismatch repair, 419 - Gene therapy, 281-283
 - for renal cell cancer, 81-91
 - methods of, 279-280 - Germ cell tumor, cure of, 641
 - Gestational trophoblastic disease
 - biologic processes of, 96
 - chemotherapy in, 147
 - CNS metastasis of, 137-139
 - CT of, 134
 - definition of, 96
 - diagnosis of, 172-173
 - DNA content in, 143
 - Doppler sonography of, 133-134
 - epidemiology of, 109-113
 - FIGO staging of, 145
 - flow cytometry in, 106
 - genetic analysis of, 113-120
 - HCG levels in, 144-147
 - hepatic metastasis of, 137
 - high-risk, *see* High-risk gestational trophoblastic disease
 - histogram in, 143
 - histopathology of, 142-143
 - imaging of, 130-141
 - immunocytochemistry in, 106
 - infertility following, 196
 - karyotyping in, 106
 - malignant, *see* Malignant gestational trophoblastic disease
 - metastatic, whole brain radiation therapy for, 185-190
 - metastatic sites of, 137
 - MRI of, 134-135
 - NIH classification of, 146
 - nonmetastatic complications of, 139
 - nonvillous, 116-117
 - nuclear medicine in, 135-136
 - overview of, 95
 - pathology of, 96-109
 - persistent, reproduction following, 194-195
 - ploidy analysis in, 106
 - prognostic variables in, 142-148
 - pulmonary metastasis of, 136-137
 - recurrent, 182

Gestational trophoblastic disease (Continued)

- reproduction following, 193-197
 - sonography of, 130-133
 - staging of, 142-148
 - steroids for, 187
 - therapy of, infertility following, 196
 - vaginal metastasis of, 139
 - villous, 113-116
 - WHO prognostic index score for, 146
- Glioma, astrocytoma-type of, 531-532
- Glutaraldehyde, 456
- Graft, IL-7 and, 112
- Graft engineering, 277-278
- Granulocyte-colony stimulating factor
 - in breast cancer, 562
 - for chemotherapy rescue, 518-519
- Granulocyte-macrophage colony-stimulating factor, 308
 - for chemotherapy rescue, 518-519
 - tumor vaccine cells and, 86
- Growth factor(s)
 - in chemotherapy rescue, 519
 - identification of, 204

Harvesting, see Stem cell harvesting**HCG, see Human chorionic gonadotropin****HD, see Hodgkin's disease****Head and neck cancer**

- adjuvant therapy in, 540-552
- chemoradiotherapy in, 545-548
- chemotherapy alternating with radiotherapy in, 547
- chemotherapy following radiotherapy in, 547
- cisplatin, 5-FU regimen in, 540
- cisplatin, 5-FU, radiotherapy regimen in, 546-548
- combined modality therapy in, 548
- neoadjuvant therapy in, 540-552
- new prognostic indicators for, 549
- organ preservation in, 543-545
- prognostic subgroups in, 548-549

Hematopoietic stem cell(s)

- asynchronous division of, 210-211
- biology of, 210-217
- cytokines and, 213-214
- development of, extracellular regulation of, 213
- developmental biology of, 212-216
- division of, 212-213
- immunocytochemical isolation of, 211-212
- isolation of, 211-212
- peripheral blood circulation of, 216
- physical isolation of, 212
- stochastic differentiation of, 213
- sub-cellular events and, 214-216

Hemorrhage, in polycythemia rubra vera, 312**Hemorrhagic cystitis, due to stem cell harvesting, 264****Hepatic artery embolization, for hepatic metastases, 503****Hepatic artery infusion**

- in colorectal cancer, 501-503
 - toxicities of, 502-503
 - trials of, 502
- Hepatic artery ligation, for hepatic metastases, 503
- Hepatic metastasis, PET imaging of, in colorectal cancer, 465-466

Hepatic resection

- complications of, 497
- hepatic anatomic segments in, 495, 496
- margins in, 498
- in metastatic colorectal cancer, 495-500
- recurrence following, 499
- repeat, results of, 500
- total vascular isolation in, 497

Hepatic-directed therapy, in colorectal cancer, 494-508**Hepatocellular cancer, percutaneous ethanol injection therapy in, 504****Hereditary nonpolyposis colorectal cancer, hereditary factors in, 418-419****Hertig grading system, 101****HHT, in chronic myelogenous leukemia, 400-401****High-dose chemotherapy**

- as conditioning regimen, complications of, 264, 265-268
- cost-effectiveness of, 244-245
- future directions in, 245-246
- hematopoietic progenitor cell support and, in ovarian cancer, 250-262
- intraperitoneal, 252-253
- multiple sequential, hematopoietic progenitor cell support for, 257-258

in newly diagnosed ovarian cancer, 256-257**quality of life following, 244****rationale for, 205****toxicities of, 243-244****trials of, in breast cancer, 563****High-risk gestational trophoblastic disease, 172-184**

- combination chemotherapy in, 178
- drug-resistant, 180-181
- surgery for, 181
- therapy monitoring in, 181-182
- treatment of, 177-182
- triple-agent chemotherapy in, 177
- weekly chemotherapy in, 178

Hodgkin's disease

- autologous marrow reinfusion regimens in, 224-226
- marrow fibrosis in, 369

Homing mechanism, of stem cells, 278**Hormonal therapy**

- adjuvant, in breast cancer, 555-556
- chemotherapy plus, in breast cancer, 556-558
- in adjuvant therapy, for melanoma, 649

Hormones, in renal cell cancer, 52**Human chorionic gonadotropin**

- alpha subunit of, 122
- beta subunit of, 122
- biological properties of, 122-123
- carbohydrate moieties of, 121-122
- carbohydrate role in, 123
- immunoradiometric assay of, 125
- levels of, in gestational trophoblastic disease, 144
- molecule of, 121-122
- nonradioisotopic measurement of, 125-126
- quantitative measurement of, 123-126
- radioimmunoassay of, 123-125
- receptor binding of, 123
- reference preparations of, 126-127
- subunit structure of, 121

- Human placental lactogen, 104
- Hydatidiform mole
chemoprophylaxis of, 157-160
contraception and, 153-154
diagnostic studies of, 149-150
early, 98
follow-up of, 153, 154
management of, 151-153
nonneoplastic complications of, 150-151
prophylactic chemotherapy for, reproduction following, 195
symptoms of, 149
treatment of, indications for, 154
- Hydroxyurea
in adjuvant therapy, for melanoma, 647-649
in chronic granulocytic leukemia, 387-388
in chronic myelogenous leukemia, 396-397
in essential thrombocythemia, 337
in gestational trophoblastic disease, 147
in polycythemia rubra vera, 316-317
prior to interferon alpha therapy, 399
- Hypereosinophilic syndrome, 362
- Hyperproliferation, in colon cancer, 442
- Hypocalcemia, due to stem cell harvesting, 265
- Hypotension, due to stem cell harvesting, 265
- ICRF-187, in renal cell cancer, 47
- Idarubicin, in renal cell cancer, 47
- Ifosfamide
for invasive bladder cancer, 625
randomized trials of, in NSCLC, 577
with or without mesna, in renal cell cancer, 47
- IGF-1, 214
- IL, see Interleukin
- Imaging, new techniques of, in colorectal cancer, 448-471
- Immobilization, active specific, for melanoma, 653-654
- Immunotherapy, in gastric cancer, 593-594
- Immunocytochemistry, in gestational trophoblastic disease, 106
- Immunofluorometric assay, of human chorionic gonadotropin, 126
- Immunohistochemical marker, in head and neck cancer, 549
- Immunological agents, in renal cell cancer, 53-54
- Immunomodulation, 278-279
- Immunopotentiation, for melanoma, 654-655
- Immunoradiometric assay, of human chorionic gonadotropin, 125
- Immunotherapy
adjuvant, in colorectal cancer, 481
adoptive, IL-2 plus, 13
for melanoma, 650-653
genetically modified cell-based, rationale for, 81-82
surgery plus, in renal cell cancer, 31-32
with cytokeratinic antigen 17-1A, 425
- Indium, radiolabeled, for imaging, 449
- Inferior vena cava, in renal cell cancer, 30-31
- Intercalating agents, in renal cell cancer, 53
- Interferon
cimetidine plus, 44
in combination regimens, 54
in essential thrombocythemia, 338
flouxuridine plus, 46
flutamide plus, 47
- Interferon (Continued)
5-FU plus, 47
for melanoma, 649-650
in neoadjuvant therapy, for head and neck cancer, 541
- Interferon-alpha, in polycythemia rubra vera, 318
- Interferon alpha, 309
in chronic granulocytic leukemia, 387-388
in chronic myelogenous leukemia, 396-397, 398
in 5-FU biochemical modulation, 511-513
low-dose IL-2 plus, 69-70
response to, in chronic myelogenous leukemia, 400
therapy with, guidelines for, 399-400
- Interferon, flouxuridine, folinic acid regimen, in renal cell cancer, 46
- Interleukin, stem cell growth and, 213-214
- Interleukin-2
in chemotherapy toxicity rescue, 519
equivalent doses of, 68
high-dose
LAK cells with, 63-64
regimen with, 61
in renal cell cancer, 61-66
standard dose v, 64-65
therapy results with, 63
toxicity of, 61-63
use of, 65
LAK cells plus, phase II trials of, 76
low-dose
immunological effects of, 67-68
interferon alpha plus, 69-70
monotherapy with, 68-69
other agents plus, 69-71
in renal cell cancer, 67-73
tumor-infiltrating lymphocytes plus, 279
phase I-II trials of, 77
UCLA trials of, 78
- Interleukin-3, 309
- Interleukin-6, plasma levels of, in reactive thrombocytosis, 336
- Interleukin-7
- International reference standard, for human chorionic gonadotropin, 126-127
- Intraepithelial lymphocyte, 11
- Intraoperative ultrasound
for liver metastasis detection, 495
in colorectal cancer, 456-457
- Intraperitoneal therapy, high-dose, in ovarian cancer, 252-253
- Invasive hydatidiform mole
MRI of, 136
pulmonary metastasis of, 137
sonography of, 133, 134
- Iodine, radiolabeled, for imaging, 449
- Irinotecan, in colorectal cancer, 516
- Iscador, in renal cell cancer, 48
- K-ras gene, in colorectal cancer, 423-424
- K-ras mutation
frequency of, 420
in colorectal cancer, 419

- Karyotyping, in gestational trophoblastic disease, 106
 53-Kd nuclear protein, 420
 Kit ligand, stem cell growth and, 213-214
 KL receptor, 214
 Krigel, MD, Robert L, in memorium, 201
- Laboratory values, in polycythemia rubra vera, 311
 LAK cells, see Lymphokine activated killer cell(s)
 Lead time bias, in colon cancer, 434
 Length bias, in colon cancer, 434
 Leucine zipper, 215
 Leucovorin, see Folinic acid
 Leukemia
 acute, in polycythemia rubra vera, 314, 363-364
 chronic basophilic, 381
 chronic eosinophilic, 381
 chronic myeloid types of, 381
 following chlorambucil, 314
 juvenile chronic myeloid, 381
 Ph-positive acute, 361
 terminology in, 380
 Leukocyte-conditioned medium, 308
 Leukoerythroblastosis, 367
 Leukopenia, following high-dose conditioning regimen, 266
 Levamisole, 5-FU regimen
 in adjuvant therapy, for melanoma, 647-649
 in chemoradiotherapy, for rectal cancer, 617-618
 in colon cancer, 605-606
 in colorectal cancer, 426-428, 477-480
 in combination chemotherapy, for breast cancer, 239
 for melanoma, 650-651
 in NSCLC, 573-576
 trials of, 478-480
- Liver
 anatomic segments of, in hepatic resection, 495, 496
 assessment of, in metastatic colorectal cancer, 494-495
 gestational trophoblastic disease metastatic to, 137
 intraoperative ultrasound of, 457
 metastasis to, 179-180
 radiation therapy for, 188-190
 resection of, *see* Hepatic resection
 Liver function test, for metastasis detection, 495
 Lomustine
 amphotericin B plus, in renal cell cancer, 48
 in chemoradiotherapy
 for NSCLC, 578
 for rectal cancer, 614
 for melanoma, 651
 postoperative, in gastric cancer, 590-592
 value of, in rectal cancer, 616
 Lomustine, procarbazine, vincristine regimen, in high-grade astrocytoma, 533
 Lomustine, vincristine, 5-FU regimen, in colorectal cancer, 427-428
 Long-term colony initiating cell, 203, 210
 Lonidamine, in renal cell cancer, 48
 L-phenylalanine mustard, in adjuvant chemotherapy, for breast cancer, 553-554
 Lung, gestational trophoblastic disease metastatic to, 136-137
 Lung cancer
 incidence of, 571
- Lung cancer (*Continued*)
 non-small cell
 adjuvant radiotherapy in, 572
 adjuvant therapy in, 572-576
 adjuvant therapy trials in, 573
 chemoradiotherapy in, 578-579
 chemoradiotherapy v radiation in, 578
 neoadjuvant therapy in, 576
 neoadjuvant therapy trials in, 577-578
 new combination chemotherapy regimens in, 579
 perioperative chemotherapy defined in, 571
 perioperative therapy of, 571-581
 single-institution phase II data in, 576-577
 surgery in, 572
- Luteinizing hormone-releasing hormone, in breast cancer, 558
 Lymph node dissection
 elective, for melanoma, 656-657
 in upper gastrointestinal tract cancers, 586-587
 Lymph nodes, endosonographic assessment of, 455
 Lymphokine activated killer cell(s)
 adherent, 375
 IL-2 plus, phase II trials of, 76
 in renal cell cancer, 75-76
- Lymphoma
 high-dose therapy in, stem cell infusion for, 218-229
 of CNS
 adjuvant therapy of, 536-537
 cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen for, 537
 cyclophosphamide, doxorubicin, vincristine, prednisone regimen for, 537
 neoadjuvant therapy of, 536-537
- Mafosfamide
 in renal cell cancer, 48
 in tumor purging, 274
- Magnetic resonance imaging
 in colorectal cancer, 457-462
 in gestational trophoblastic disease, 134-135
 future trends in, 461-462
 for liver metastasis detection, 494-495
- Major BCR, in chronic granulocytic leukemia, 344
 Major BCR-ABL fusion, in chronic granulocytic leukemia, 345
 Major histocompatibility complex genes, expression of, 82-83
 Malignant gestational trophoblastic disease
 ABO blood type in, 176
 antecedent pregnancy in, 175-176
 classification of, 173-176
 classification systems in, 176
 clinicopathologic diagnosis of, 176
 duration of, 175
 FIGO staging of, 174
 HCG levels in, 175
 metastatic sites in, 175
 modified WHO prognostic index score for, 174
 nonmetastatic, 174-175
 prior chemotherapy in, 176
- Marker(s)
 candidate, in colon cancer, 443
 in colon cancer screening, 442

- MDR 1 gene, 282
 in clinical trials, 24-26
 in-gel renaturation for, 17
 localization of, 19
- MDR 2 gene, in-gel renaturation for, 17
- Medulloblastoma
 adjuvant therapy of, 536-537
 neoadjuvant therapy of, 536-537
- Megakaryocyte-platelet-derived growth factor, in bone marrow fibrosis, 328
- Megestrol acetate, for melanoma, 649
- Melanoma, cutaneous
 active specific immunization for, 653-654
 adjuvant radiotherapy for, 657
 adjuvant therapy for, 647-661
 antigen-supplemented whole tumor cells for, 655
 bacille Calmette-Guerin for, 650-652
Corynebacterium parvum for, 652-653
 elective lymph node dissection for, 656-657
 hormonal therapy for, 649
 immunopotentiation for, 654-655
 incidence of, 647
 interferon for, 649-650
 levamisole for, 650-651
 megestrol acetate for, 649
 nonspecific immunotherapy for, 650-653
 nonsystemic adjuvant therapy for, 656-657
 vaccines for, 653-655
 vitamin A for, 656
- Melphalan
 high-dose, in multiple myeloma, 230
 in high-dose combination regimen, for ovarian cancer, 256-257
 mitoguazone plus, in renal cell cancer, 48
 in peripheral blood progenitor cell transplantation, 233
 prednisone plus, in multiple myeloma, 230
 in renal cell cancer, 48
- Melphalan, carmustine, cytarabine regimen, high-dose, 220
- Menogaril, in renal cell cancer, 48
- Merocyanine 540, 275-276
- Mesna, ifosfamide plus, in renal cell cancer, 47
- Metals, in renal cell cancer, 52
- Methotrexate
 dose intensity of, in breast cancer, 561-563, 564
 dose sequencing of, in breast cancer, 563-564
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147, 177
 high-dose trials of, in breast cancer, 563
 for invasive bladder cancer, 625, 627
 postoperative, in gastric cancer, 590-592
- Methotrexate, 5-FU, doxorubicin regimen, in gastric cancer, 593
- Methotrexate, cisplatin, vinblastine regimen, for invasive bladder cancer, 625, 627
- Methotrexate, cyclophosphamide, 5-FU regimen, in breast cancer, 238-240, 553
- Methotrexate, procarbazine, cyclophosphamide regimen, intra-arterial, in astrocytoma, 515
- Methotrexate, vinblastine, doxorubicin regimen, for invasive bladder cancer, 625, 627
- Methyl lomustine, 5-FU, vincristine regimen, in colorectal cancer, 427-428
- Methylation, DNA, in colorectal cancer, 421
- N-Methylformamide, in renal cell cancer, 48
- Microsatellite, definition of, 422
- Minor BCR, in chronic granulocytic leukemia, 344
- Minor response, definition of, 42
- Misonidazole, cyclophosphamide plus, in renal cell cancer, 44-45
- Missense mutation, 420
- Mitoguazone
 in renal cell cancer, 48
 melphalan plus, 48
- Mitolactol, in renal cell cancer, 48
- Mitolozomide, in renal cell cancer, 48
- Mitomycin C, 594
 in chemoradiotherapy, for head and neck cancer, 546-547
 in neoadjuvant trials, for head and neck cancer, 542-543
 postoperative, in gastric cancer, 590-592
 randomized trials of, in NSCLC, 577
- Mitoxantrone, in renal cell cancer, 48
- MLH-1 gene, 419
 in colorectal cancer, 422
- Mobilization, of stem cells, complications of, 263-265
- Modulating agents, in renal cell cancer, 53
- Molar pregnancy
 chemoprophylaxis in, 157-160
 complete, definition of, 96
 diagnostic problems in, 102
 differential diagnosis of, 97
 implantation site in, 101-102
 partial, definition of, 96, 98-100
 pathologic features of, 96-103
 prognostic factors in, 100-102
 repeat, incidence of, 195
 reproduction following, 194, 195
- Monoclonal antibody(ies)
 availability of, for radioimmunodetection, 448
 in colon cancer, 606
 radiolabeled, clinical experience with, 36-37
 reactive, with renal cell carcinoma, 34-35
- Monoclonal antibody C219, 21
- Monoclonal antibody G250
 chimerized, 37
 for anti-idiotype antibodies, 37-40
 mediated therapy, 35-36
 in renal cell cancer, 34-41
- Monoclonal antibody H241, 21
- Monoclonal antibody MRK16, 26
- Monosomy 7, 351
- Mouse, severe combined immunodeficiency, engraftment in, 12
- MRI, see Magnetic resonance imaging
- MSH-2 gene, 419
 in colorectal cancer, 422
- Mucin, in colorectal cancer, 426
- Multidrug resistant associated protein, 17, 18
- Multiple drug resistance
 description of, 17-18
 inhibition of, 22-24
 in renal-cell carcinoma, 19-22

- Multiple myeloma
allogeneic marrow transplant data in, 231-232
blood progenitor cell transplantation in, 232-234
dose intensity without stem cell rescue in, 230
peripheral blood myeloma cells in, 234
transplantation in, 230-237
- Mutated in colon cancer gene, 418
location of, 419-420
- Mutator phenotype, in colorectal cancer, 422-423
- Myelofibrosis, in chronic granulocytic leukemia metamorphosis, 392
- Myeloproliferative disorder
chromosome abnormalities in, 341-354
chronic, 327
hematopathologic findings in, 355-373
introduction to, 305-306
nonspecific, 349-350
nonspecific chromosome abnormalities in, 350-351
- Nasopharyngeal cancer, neoadjuvant pilot trials in, 541-542
- National Marrow Donor Program, 407
- Navelbine, in renal cell cancer, 48
- Neoadjuvant chemotherapy
adjuvant v, for invasive bladder cancer, 629-630
in CNS lymphoma, 536
disadvantages of, 534-535
in ependymoma, 536
in esophageal cancer, 584
in gastric cancer, 584, 592-593
in head and neck cancer, 540-552
for organ preservation, 543-545
pilot trials of, 541-542
randomized trials of, 542-543
survival following, 540-541
- in high-grade astrocytomas, 535-536
- for invasive bladder cancer, 625-632
- in medulloblastoma, 536
- in NSCLC, 571-581
- for organ preservation, in head and neck cancer, 543-545
- overview of, 529, 530-539
- in pancreatic cancer, 584
- in prostate cancer, 634
- randomized trials of, in NSCLC, 577-578
- strategies of, 534
- Nephrectomy
adjuvant, 31
immunotherapy plus, 31-32
radical, 29
- Network theory, 38
- Neural cell adhesion protein, 421
- Neutropenia
following high-dose conditioning regimen, 265-268
post-transplant, 267
- Neutrophil alkaline phosphatase score, 380
in chronic granulocytic leukemia, 386, 393
- Neutrophils, engraftment rates of, 266
- Nifedipine
as chemosensitizing agent, 23
vinblastine plus, 50
- NIH classification, of gestational trophoblastic disease, 146
- Nimodipine, as chemosensitizing agent, 23
- Nitredipine, as chemosensitizing agent, 23
- Nitrosourea, in high-grade astrocytoma, 533
- Non-Hodgkin's lymphoma
autologous stem cell transplantation in, mortality following, 222
- PBSC reinfusion in, 221-223
- relapsed, autologous bone marrow regimens in, 219-221
- stem cell transplant timing in, 219
- total body irradiation in, 220-221
- N-phosphonacetyl-L-aspartic acid, in 5-FU biochemical modulation, 511
- N-ras gene, 214
in colorectal cancer, 423-424
- NSCLC, see Lung cancer, non-small cell
- Nuclear medicine, in gestational trophoblastic disease, 135-136
- Octreotide, 517-518
- OK432, 594
- Oncogene(s)
in colorectal cancer, 423-424
p53, 420
- Organ preservation, neoadjuvant therapy for, in head and neck cancer, 543-545
- Ornithine decarboxylase, detection of, in colon cancer, 442-443
- Ovarian ablation, in breast cancer, 558-559
- Ovarian cancer
chemotherapy dose intensity in, 250-251
epithelial, chemotherapy resistance in, 250
hematopoietic progenitor cell support in, 252-262
marrow contamination in, 259
newly diagnosed, high-dose chemotherapy in, 256-257
refractory, cisplatin in, 251-252
sensitive epithelial, high-dose chemotherapy in, 253-254
- Oxaliplatin, 517
- P exotoxin, 26
- p53
in bladder cancer, 630-631
in colorectal cancer, 420
in head and neck cancer, 549
overexpression of, clinical significance of, 421
wild-type, 420
- Paclitaxel
dose intensity of, in breast cancer, 562-563
for invasive bladder cancer, 625
in mobilization, 258
in renal cell cancer, 49
- PALA, in renal cell cancer, 49
- Pancreatic cancer
adjuvant therapy in, 582-599
chemoradiotherapy in, 584-585
failure pattern in, 582-584
incidence of, 582
neoadjuvant therapy of, 584
patient selection in, 585-586
postoperative chemotherapy in, 586-587
radioimmunodetection of, 450
surgery in, 586-587
- Partial hydatidiform mole, 99, 115-116
reproduction following, 193-194

- Partial hydatidiform mole (*Continued*)
 sonography of, 132
 villous contour of, 100
- Partial response, definition of, 42
- PBSC, see Peripheral blood stem cell(s)
- PCNU, in renal cell cancer, 48
- Peptic ulcer, in polycythemia rubra vera, 312
- Percutaneous ethanol injection therapy, for hepatic metastases, 504
- Periampullary duodenal carcinoma, hereditary factors in, 418-419
- Peripheral blood progenitor cell transplantation
 autologous BMT v. in breast cancer, 242-243
 in multiple myeloma, 232-234
 in ovarian cancer, 257-258
- Peripheral blood stem cell(s)
 circulating, evidence for, 202
 collection of, 204-205
 following high-dose HD therapy, 225-226
 harvesting of, *see* Stem cell harvesting
 identification of, 202-204
 infusion of, high-dose trials of, in breast cancer, 563
 mobilization complications of, 263-265
 mobilization of, 204
 reinfusion of
 in non-Hodgkin's lymphoma, 221-223
 in recurrent HD, 225
- Peripheral blood stem cell transplantation
 autologous, mortality following, 222
 autologous v allogeneic, 218-219
 blood centers and, 283-284
 in breast cancer, 238-249
 in chronic myelogenous leukemia, 401
 complications of, 263-270
 early, 205-206
 future directions in, 206-207, 271-290
 gene therapy in, 279-283
 graft engineering in, 277-278
 history of, 203
 immunomodulation in, 278-279
 intravenously transplanted, homing of, 278
 reinfusing lymphoma in, 223-224
 tumor decontamination in, 271-277
 tumor detection in, 272-273
 tumor purging in, 273
- Peripheral progenitor cell, cryopreserved, high-dose trials of, 563
- Persistent nonmetastatic gestational trophoblastic disease, 161-165
 chemotherapy for, 162-163
 diagnosis of, 161-162
 long-term prognosis of, 164
 outcomes in, 164
 surgery for, 163
- Personnel, for colon cancer screening, 441
- PET, *see* Positron emission tomography
- P-glycoprotein(s)
 expression of, 18-19
 in clinical trials, 24-26
 MDR 1 a, 18
- Philadelphia chromosome, in chronic granulocytic leukemia, 344-346, 380
- Phlebotomy
 aspirin plus, 316
 dipyradomole plus, 316
 in polycythemia rubra vera, 315
 thrombosis associated with, 315-316
- N-Phosphonacetyl-L-aspartic acid, in renal cell cancer, 49
- Phosphorus, radioactive, in polycythemia rubra vera, 315
- Pipbroman, in polycythemia rubra vera, 315
- Pirarubicin, in renal cell cancer, 48
- Piroxantrone, in renal cell cancer, 48
- Placenta, examination of, methods of, 117-118
- Placental site trophoblastic tumor, 116
 definition of, 104
 differential diagnosis of, 105
 pathology of, 104-105
 sonography of, 133
 therapy for, 163-164
- Platelet anti-aggregating therapy, in polycythemia rubra vera, 316
- Platelet distribution width, in polycythemia rubra vera, 312
- Platelet nucleotide ratio, in polycythemia rubra vera, 312
- Platelet-derived growth factor, in bone marrow fibrosis, 328
- Ploidy analysis, in gestational trophoblastic disease, 106
- PMS1, 419
 in colorectal cancer, 422
- PMS2, 419
 in colorectal cancer, 422
- Poly IC-LC, in renal cell cancer, 49
- Polyclonal antiplacental alkaline phosphatase, 106
- Polycythemia rubra vera, 307-326
 acute leukemia in, 314
 busulfan in, 317
 clinical features of, 310-312
 common signs in, 310
 course of, 313-314
 cytogenetics of, 346-348
 diagnosis of, 312-313
 diagnostic criteria for, 363
 differential diagnosis of, 364
 erythropoietin levels in, 308
 hydroxyurea in, 316-317
 incidence of, 307
 interferon-alfa in, 318
 laboratory abnormalities in, 311
 major features of, 368
 pathophysiology of, 307-310
 in patients under 40, 319
 phlebotomy in, 315
 pipbroman in, 318
 primary v secondary, 312-313
 proliferative stage of, 362
 special considerations in, 319-320
 spent phase of, 363
 surgery in, 319-320
 symptoms in, 310
 thrombo-hemorrhagic complications of, 311-312
 thrombocytosis in, 319
 treatment by age in, 319
 treatment of, 314-319

- Polymerase chain reaction, in stem cell tumor detection, 272-273
- Polyp(s)
 colonic, familial clustering of, 441
 detection of, in colon cancer, 437-439
- Portal vein adjuvant therapy
 in colon cancer, 604-605
 in colorectal cancer, 476-477
 trials of, 477
- Positive predictive value, in colon cancer, 434
- Positron emission tomography
 in colorectal cancer, 462-466
 in gestational trophoblastic disease, 135-136
 radio pharmaceuticals for, 463-464
- Postpolycythemia myeloid metaplasia, 313-314, 363
- Prednisone
 in adjuvant hormonal therapy, of breast cancer, 555
 melphalan plus, in multiple myeloma, 230
- Prednisone, cyclophosphamide, doxorubicin, vincristine, regimen, in CNS lymphomas, 537
- Pregnancy, essential thrombocythemia and, 338-339
- Pringle maneuver, 496
- Procarbazine, lomustine, vincristine regimen, in high-grade astrocytoma, 533
- Procarbazine, methotrexate, cyclophosphamide regimen, intra-arterial, in astrocytoma, 535
- Prodruk, 5-FU, 513-514
- Progesterone, as chemosensitizing agent, 23
- Prognostic factor(s)
 in colorectal cancer, 472-473
 DNA ploidy as, in colorectal cancer, 473
 in hepatic resection, 498-500
- Prostate cancer
 adjuvant systemic therapy of, 633-640
 adjuvant therapy of, 634-638
 early, conventional therapy of, 634-636
 heterogeneity of, therapy implications of, 633-634
 incidence of, 633
 neoadjuvant therapy of, 634
 stage classification of, 634
- Protein kinase-C, detection of, in colon cancer, 442-443
- Protein-bound polysaccharide, 594
- PU.1, 215
- Pulstility index, definition of, 133
- Pump
 implantable, for hepatic arterial infusion, 501-502
 intrahepatic, 502-503
- Purines, in renal cell cancer, 53
- Pyrimidines, in renal cell cancer, 52-53
- Quinidine
 as chemosensitizing agent, 23
 vinblastine plus, 50
- Radiation therapy
 of brain, 185-188
 for gestational trophoblastic disease, 185-190
 for hepatic metastases, 504-505
 of liver, 188-190
- Radioimmunoassay, of human chorionic gonadotropin, 123-125
- Radioimmunodetection
 of colorectal cancer, 448-451
 of pancreatic cancer, 450
 radionuclides for, 449
- Radioimmunoscintigraphy, in gestational trophoblastic disease, 135-136
- Radiolabeling, of monoclonal antibodies, clinical experience with, 36-37
- Radiopharmaceuticals
 for PET imaging, 463-464
 for radioimmunodetection, 449
- Radiotherapy
 adjuvant
 for melanoma, 657
 in NSCLC, 572
 in rectal cancer, 618
 in agnogenic myeloid metaplasia, 331
 chemotherapy alternating with, in head and neck cancer, 547
 chemotherapy plus, *see Chemoradiotherapy*
 combination chemotherapy plus
 for head and neck cancer, 545-547
 randomized trials of, 546
 high-dose chemotherapy plus, in breast cancer, 563
 in neoadjuvant trials, for head and neck cancer, 542-543
 postoperative, in colon cancer, 606-607
 preoperative, randomized trials of, 612-613
 in primary brain tumor, 530
 sandwich, in rectal cancer, 616
 sphincter-sparing surgery plus, in rectal cancer, 618-621
 Radiotherapy, cisplatin, 5-FU regimen, in head and neck cancer, 547-548
- Ras gene, in colorectal cancer, 423-424
- Raynaud's phenomenon, in polycythemia rubra vera, 312
- RBI gene, 349
- Reactive thrombocytosis
 clinical features of, 336
 clonal v, 336
 conditions associated with, 335
 C-reactive protein plasma levels in, 336
 essential thrombocythemia v, 335
 IL-6 plasma levels in, 336
- Receptor binding, in human chorionic gonadotropin, 123
- Rectal cancer
 adjuvant radiotherapy in, 618
 adjuvant therapy in, need for, 611
 adjuvant trials in, 481-482
 chemoradiotherapy issues in, 617-618
 CT staging of, 454
 endoscopic staging of, 454
 folinic acid in, 617-618
 5-FU in, 615
 levamisole in, 617-618
 local excision plus radiotherapy in, 619-620
 lomustine in, 616
 ongoing adjuvant trials in, 483
 postoperative adjuvant therapy in, 613-616, 616
 preoperative adjuvant therapy in, 611-613, 616
 preoperative chemoradiotherapy trials in, 613
 preoperative radiation plus surgery in, 620-621
 preoperative radiotherapy trials in, 612-613
 preoperative v postoperative adjuvant therapy in, 616-617

- Rectal cancer (*Continued*)
 radiotherapy in, 618-621
 sphincter-sparing surgery in, 618-621
 tumor markers in; as response prognosticators, 618
- Renal-cell carcinoma
 advanced, chemotherapy for, 42-60
 autolymphocyte cellular therapy in, 74-75
 cellular therapy in, 74-80
 familial, von Hippel-Lindau mutations in, 6
 gene therapeutic approaches to, 12-14
 gene therapy for, 81-91
 genetics of, 3-8
 high-dose IL-2 in, 61-66
 immunotherapeutic strategies in, 9-10
 incidence of, 3, 43
 introduction to, 1-2
 LAK cellular therapy in, 75-76
 low-dose IL-2 in, 67-73
 metastatic, surgery plus immunotherapy in, 31-32
 monoclonal antibodies reactive with, 34-35
 monoclonal antibody G250 in, 34-41
 mortality rates of, 43
 multiple drug resistance in, 19-22
 murine, studies in, 9-16
 nephron-sparing surgery in, 29-33
 radical nephrectomy in, 29
 sporadic, von Hippel-Lindau mutations in, 5-6
 tumor-infiltrating lymphocyte cellular therapy in, 76-78
 vena caval involvement in, 30-31
- Renca model, T lymphocyte-mediated immune responses against, 10
- Replication error, in colorectal cancer, 422-423
- Reproduction
 counseling for, 195-196
 following complete hydatidiform mole, 193
 following partial hydatidiform mole, 193-194
 following persistent gestational trophoblastic disease, 194-195
 following repeat molar pregnancy, 194
- Rescue, from chemotherapy toxicity, agents for, 517-519
- Reserpine, as chemosensitizing agent, 23
- Resistive index, definition of, 133
- Response, definition of, 42
- Retroperitoneal lymph node dissection, in stage II nonseminomatous testis cancer, 641-642
- Rhodamine-123, 211
- RNA, MDR 1, levels of, 20
- Rules of evidence, for screening, 488-489
- Screening
 age in, 440
 for colon cancer, 433-447
 intervals in, 440
 positive family history in, 440-441
 rules of evidence for, 488-489
- Semustine, 5-FU regimen
 in adjuvant chemotherapy, 474-475
 in adjuvant therapy, for melanoma, 647-649
 in chemoradiotherapy, for rectal cancer, 614
 in colorectal cancer, 475
- Severe combined immunodeficiency mice, engraftment in, 12
- Sialosyl-Tn antigen, in colorectal cancer, 426
- Sigmoidoscopy
 in colon cancer, 437-439
 rigid, 438
- Single strand conformational polymorphism gel, in von Hippel-Lindau disease, 4
- Sparfosic acid, in renal cell cancer, 49
- Sphincter-sparing surgery
 preoperative radiation plus, 620-621
 radiation plus, 618-621
- Spindle inhibitors, in renal cell cancer, 51-52
- Spirogermanium, in renal cell cancer, 49
- Spiromustine, 533
- Splenectomy, in agnogenic myeloid metaplasia, 330-331
- Stabilization of disease, definition of, 42
- Stage distribution, in colon cancer, 434
- Staging
 surgical, 472-473
 TNM, 472-473
- Stem cell harvesting
 complications of, 263-265
 gene therapy following, 279-283
 graft engineering following, 277-278
 immunomodulation following, 278-279
 positive selection in, 275-276
 purging plus positive selection in, 276-277
 tumor decontamination in, 271-277
 tumor purging in, 273-274
- Stem cell kinase-1 ligand, hematopoietic stem cell growth and, 213-214
- Steroids, in peripheral blood progenitor cell transplantation, 233
- STK-1, 213
- Streptozotocin, in renal cell cancer, 49
- Subclone, 343
- Suicide gene, 282-283
- Sulofenur, in renal cell cancer, 49
- Suramin, in renal cell cancer, 49
- Surgery
 in esophageal cancer, 586-587
 in gastric cancer, 586-587
 immunotherapy plus, 31-32
 in neoadjuvant trials, for head and neck cancer, 542-543
 nephron-sparing, 29-33
 in NSCLC, 572
 in pancreatic cancer, 586-587
 in polycythemia rubra vera, 319-320
 in primary brain tumor, 530
 in rectal cancer, 612
 sphincter-sparing, see Sphincter-sparing surgery
 trials of, in NSCLC, 573-576
- Surveillance, adjuvant therapy *v.* in testis cancer, 643
- T(5;2)(q31,p12) syndrome, 349-350
- T(8;9)(p11,34), 351
- T(8;9)(q22,34), 351
- T(9;2)(q34,q11.2)
 in chronic granulocytic leukemia, 344-346
 in myeloproliferative disorders, 341-343
- T-1 weighted image, definition of, 458
- T-2 weighted image, definition of, 458
- TAG-72 antigen, radioimmunodetection of, 448

- Tamoxifen
 in adjuvant chemotherapy, 553-554
 in chemohormonal therapy, 557
 as chemosensitizing agent, 23
 dose intensity of, 562-563
 in renal cell cancer, 49
- Tauromustine, in renal cell cancer, 49
- Taxol, *see* Paclitaxel
- Taxotere, in renal cell cancer, 49
- TE, in MRI, definition of, 458
- Technetium, radiolabeled, for imaging, 449
- Telomeres, 212
- Teniposide, in renal cell cancer, 49
- Testis cancer
 retroperitoneal metastases of, pathologic staging of, 642
 stage II
 prognostic factors in, 643
 relapse incidence in, 644
 stage II nonseminomatous
 adjuvant therapy in, 641-646
 staging in, 641-642
 surveillance v adjuvant therapy in, 643
- Theca-lutein cyst(s)
 complications of, 144
 CT of, 134
 incidence of, 139
 sonography of, 135
- 6-Thioguanine, in renal cell cancer, 49
- Thiotepa
 high-dose trials of, in breast cancer, 563
 in peripheral blood progenitor cell transplantation, 233
 postoperative, in gastric cancer, 590-592
- Thoracotomy, in esophageal cancer, 586
- Thrombocytopenia, primary, *see* Essential thrombocythemia
- Thrombocytopenia, due to stem cell harvesting, 264
- Thrombocytosis
 anagrelide in, 319
 in polycythemia rubra vera, 319
 reactive, *see* Reactive thrombocytosis
- Thrombosis
 associated with phlebotomy, 315-316
 in polycythemia rubra vera, 311
- Thymidylate synthase
 as chemotherapeutic target, in colorectal cancer, 426-428
 fluorouracil inhibition of, 427
 inhibitors of, 514-515
- TNM staging, in colorectal cancer, 472-473
- Topoisomerase I inhibitor, 515-516
- Topotecan, 516
 in renal cell cancer, 49
- Toremifene, in renal cell cancer, 49
- Total body irradiation
 in matched sibling BMT, for chronic myelogenous leukemia, 406
 in multiple myeloma, 233
 in non-Hodgkin's lymphoma, 220-221
- Toxicity, of chemotherapy, protection from, 517-519
- TR, in MRI, definition of, 458
- Transcription factor, in hematopoietic cell development, 214-215
- Transfектант(s)
 antitumor effects of, 14
 production of, 13-14
- Transforming growth factor-beta, in bone marrow fibrosis, 327
- Transitional cell cancer, chemotherapy for, 625-626
- Trifluoperazine, as chemosensitizing agent, 23
- Triglycidylurazol, in renal cell cancer, 49
- Trimetrexate, in renal cell cancer, 49
- Trisomy 8, 351
- Trophoblastic tumor, nonvillous, 116-117
- Tumor-associated antigen
 in colorectal cancer, 425-426
 monoclonal antibodies reactive with, 34
- Tumor marker, in rectal cancer, as response prognosticator, 618
- Tumor purging
 chemical agents for, 274
 in stem cell collections, 273
- Tumor-infiltrating lymphocyte(s)
 IL-2 plus, 77-78
 in renal cell cancer, 76-78
 phase I-II trials of, 77
 UCLA trials of, 78
- Tumor-specific antigen, monoclonal antibodies reactive with, 34
- Tumor-targeting study, in renal-cell carcinoma, 35
- Tumorigenesis, von Hippel-Lindau mutations in, 3-8
- Turcot's syndrome, hereditary factors in, 418-419
- Ultrasoundography
 endoluminal, 452-456
 in colorectal cancer, 451-457
 rectal, for tumor infiltration depth, 453
- Ultrasound
 Doppler, *see* Doppler ultrasound
 of gestational trophoblastic disease, 130-133
 intraoperative, *see* Intraoperative ultrasound of placental site trophoblastic tumor, 133
- Ultraviolet light, 275-276
- Uracil
 florafur plus, 513
 5-FU plus, in renal cell cancer, 47
- Uracil-tegafur, trials of, in NSCLC, 575-576
- Vaccine(s)
 Ah2, 37-40
 G250-related anti-idiotype antibodies for, 37-38
 gene-transduced tumor, 84-85
 genetically altered tumor, 85-88
 for melanoma, 653-655
 strategies for, 88-90
- Vagina, gestational trophoblastic disease metastatic to, 139
- Vasquez-Osler disease, 307
- Vena cava, involvement of, in renal cell cancer, 30-31
- Verapamil, vinblastine plus, in renal cell cancer, 50
- Vinblastine
 cyclosporine-A plus, 50
 dipyridamole plus, 50
 doxorubicin plus, 50
 floxuridine plus, 46
 for invasive bladder cancer, 625
 in chemoradiotherapy, for NSCLC, 578

- Vinblastine (*Continued*)
 nifedipine plus, 50
 quinidine plus, 50
 verapamil plus, 50
Vinblastine, cisplatin, bleomycin regimen, 642-643
Vinblastine, cisplatin, methotrexate regimen, 625, 627
Vinblastine, methotrexate, doxorubicin regimen, 625, 627
Vincristine
 in adjuvant chemotherapy, 474-475
 in chemoradiotherapy, for rectal cancer, 614
 high-dose trials of, in breast cancer, 563
 in gestational trophoblastic disease, 147
 for melanoma, 654
 in peripheral blood progenitor cell transplantation, 233
Vincristine, cyclophosphamide, doxorubicin, dexamethasone regimen, in CNS lymphomas, 537
Vincristine, cyclophosphamide, doxorubicin, prednisone regimen, in CNS lymphomas, 537
Vincristine, doxorubicin, dexamethasone regimen
 in chronic myelogenous leukemia, 400-401
 in multiple myeloma, 230
Vincristine, methyl lomustine, 5-FU, regimen, in colorectal cancer, 427-428
Vincristine, procarbazine, lomustine, regimen, in high-grade astrocytoma, 533
Vindesine
 in neoadjuvant trials, for head and neck cancer, 542-543
 in renal cell cancer, 50
 trials of, in NSCLC, 575-576
Vinorelbine, in renal cell cancer, 48
Vitamin A, for melanoma, 656
Vitamin B12, in chronic granulocytic leukemia, 393
VLA-4, 213
VLA-5, 213
Volunteer bias, in colon cancer, 434
Von Hippel-Lindau disease
 clinical heterogeneity in, 4
 gene of, positional cloning for, 3-4
 incidence of, 3
 mutations of, 5-6
WHO prognostic index score
 for gestational trophoblastic disease, 146
 modified, 174
Whole brain radiation therapy
 dosing of, 187
 for metastatic gestational trophoblastic disease, 185-188
 side effects of, 188
 volume of, 187
Whole liver radiation therapy, 188
 for metastatic gestational trophoblastic disease, 188-190
 side effects of, 189-190
 volume of, 188-189
Wild-type p53 protein, 420
WR-2721, in tumor purging, 274
Yeast artificial chromosome contig, 4
ZD1694, 515

